While the hormone receptor or HER2 status has seldom been specified in previous papers, a single study [19] found predominant hormone receptor negativity among MMR-deficient breast cancers from MMR gene mutation carriers; furthermore, there was no difference in the age at onset between MMR-deficient and MMR-proficient breast cancers. Here, NR4A1 is linked to breast cancer.